Involvement of UTP in protection of cardiomyocytes from hypoxic stressThis article is one of a selection of papers from the NATO Advanced Research Workshop on Translational Knowledge for Heart Health (published in part 2 of a 2-part Special Issue).

Canadian Journal of Physiology and Pharmacology - Tập 87 Số 4 - Trang 287-299 - 2009
Asher Shainberg1,2,3, Smadar Yitzhaki1,2,3, Or Golan1,2,3, Kenneth A. Jacobson1,2,3, Edith Hochhauser1,2,3
1FMRC, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
2Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 52900, Israel
3Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, Maryland, USA.

Tóm tắt

Massive amounts of nucleotides are released during ischemia in the cardiovascular system. Although the effect of the purine nucleotide ATP has been intensively studied in myocardial infarction, the cardioprotective role of the pyrimidine nucleotide UTP is still unclear, especially in the cardiovascular system. The purpose of our study was to elucidate the protective effects of UTP receptor activation and describe the downstream cascade for the cardioprotective effect. Cultured cardiomyocytes and left anterior descending (LAD)-ligated rat hearts were pretreated with UTP and exposed to hypoxia–ischemia. In vitro experiments revealed that UTP reduced cardiomyocyte death induced by hypoxia, an effect that was diminished by suramin. UTP caused several effects that could trigger a cardioprotective response: a transient increase of [Ca2+]i, an effect that was abolished by PPADS or RB2; phosphorylation of the kinases ERK and Akt, which was abolished by U0126 and LY294002, respectively; and reduced mitochondrial calcium elevation after hypoxia. In vivo experiments revealed that UTP maintained ATP levels, improved mitochondrial activity, and reduced infarct size. In conclusion, UTP administrated before ischemia reduced infarct size and improved myocardial function. Reduction of mitochondrial calcium overload can partially explain the protective effect of UTP after hypoxic–ischemic injury.

Từ khóa


Tài liệu tham khảo

10.1254/jjp.78.113

Anversa P., 1998, Circ. Res., 83, 1, 10.1161/01.RES.83.1.1

10.1523/JNEUROSCI.5338-05.2006

Burnstock, G. 1978. A basis for distinguishing two types of purinergic receptor. In Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Edited by L. Bolis and R.W. Straub. Raven Press, New York. pp. 107–118.

10.1016/0006-2952(94)90050-7

10.1016/j.ijcard.2004.10.005

10.1016/S0143-4160(02)00056-8

10.1016/j.cardiores.2006.01.017

10.1016/S0024-3205(99)00353-7

10.1038/sj.bjp.0704748

10.1007/s11302-008-9106-2

10.1016/j.yjmcc.2005.12.012

Kajstura J., 1996, Lab. Invest., 74, 86

10.1111/j.1582-4934.2007.00133.x

10.1152/ajpheart.00393.2004

Murry C.E., 1986, Circulation, 74, 1124, 10.1161/01.CIR.74.5.1124

10.1016/0041-008X(92)90317-L

10.1016/S0022-2828(03)00009-9

Podrasky E., 1997, Am. J. Physiol., 273, H2380

Puceat M., 1996, Biochem. J., 318, 723, 10.1042/bj3180723

Ralevic V., 1998, Pharmacol. Rev., 50, 413

10.1023/A:1007209321969

10.1006/excr.1998.4134

10.1002/1098-2299(200007/08)50:3/4<324::AID-DDR16>3.0.CO;2-B

10.1006/jmcc.2001.1387

Shneyvays, V., Leshem, D., Mamedova, L.K., and Shainberg, A. 2003. Activation of adenosine A1 and A3 receptors protects mitochondria during hypoxia in cardiomyocytes by distinct mechanisms. In Myocardial ischemia and preconditioning. Edited by N.S. Dhalla, N. Takeda, M. Singh, and A. Lukas. Kluwer Academic Publishers, Boston. pp. 347–364.

10.1034/j.1399-6576.2000.440903.x

Vassort G., 2001, Physiol. Rev., 81, 767, 10.1152/physrev.2001.81.2.767

10.1007/s002100000310

10.1016/j.bcp.2005.01.018

10.1016/j.bcp.2006.07.019

10.1016/j.yjmcc.2007.07.060

10.1023/A:1026021430091

Zheng J.S., 1996, Circ. Res., 78, 525, 10.1161/01.RES.78.4.525

Thông tin
Thông tin xuất bản

Canadian Journal of Physiology and Pharmacology

Tập 87 Số 4

287-299

Thông tin tác giả